InvestorsHub Logo
Followers 82
Posts 3648
Boards Moderated 0
Alias Born 02/15/2010

Re: None

Monday, 07/27/2015 8:18:20 AM

Monday, July 27, 2015 8:18:20 AM

Post# of 460035
Dr De's Opening Thoughts: Last week

The previous week was important for biotech investors in many ways. Last week saw the AAIC phase 2a trial result announcements from Anavex (OTCQX:AVXL) for its Anavex 2-73 class drugs, which showed excellent trial results for Alzheimer's. This is about the only drug that I have come across for AD for which I would dare to use that often-futile word, "cure."

http://seekingalpha.com/article/3359015-premarket-biotech-digest-gilead-earnings-tomorrow-praluent-other-approvals?isDirectRoadblock=false&uprof=

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News